Edison is developing orally available small molecules for energy defects associated with inherited mitochondrial and neurodegenerative diseases

Edison has assembled a world-class team of multidisciplinary experts in redox drug discovery and development.

About More

A dedicated group of physicians, researchers, foundations, executives and parents of children with mitochondrial disease founded Edison in 2005. This group understood that breakthroughs occurring in university settings needed to be translated into therapeutics by a company...  

[ Continue...]

Business More

Edison’s market is inherited mitochondrial and neurodegenerative disease. The Company is focused on those indications where four criteria have been satisfied: 1) defects in the mitochondrial respiratory chain are strongly associated with the disease mechanism; 2) CoQ10 has...  

[ Continue...]

Development More

Edison’s area of expertise is in the biology of energy metabolism and in the medicinal chemistry of drugs that undergo reversible oxidation-reduction (redox), chemical reactions. Edison’s drugs are small molecules, with a molecular weight typically less than 500, that are...  

[ Continue...]

News More